Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

AGEN Company Profile and Key Details

NASDAQ : AGEN

Agenus Inc.

$2.86
-0.27-8.63%
At Close 4:00 PM
$2.94
0.08+2.80%
After-Market 07:58 PM
66.13
BESG ScoreESG Rating

AGEN Stock Price Chart

Stock Price Today

Agenus Inc. (AGEN) stock declined over -8.63%, trading at $2.86 on NASDAQ, down from the previous close of $3.13. The stock opened at $3.18, fluctuating between $2.83 and $3.23 in the recent session.

Stock Snapshot

3.13
Prev. Close
3.18
Open
67.09M
Market Cap
23.46M
Number of Shares
2.83
Day Low
3.2324
Day High
-0.26
P/E Ratio
97.58%
Free Float in %
-11.02
EPS (TTM)
-0.41
Book Value
-0.54
Cash Flow per Share
543.49K
Volume

Stock Price History Chart

DateOpenHighLowCloseVolume
Feb 27, 20253.183.232.832.86542.51K
Feb 26, 20253.093.323.033.13418.01K
Feb 25, 20253.173.273.063.09391.25K
Feb 24, 20253.363.483.143.16294.26K
Feb 21, 20253.513.513.273.32226.76K
Feb 20, 20253.443.513.353.45193.62K
Feb 19, 20253.503.563.403.48331.03K
Feb 18, 20253.563.603.453.52183.24K
Feb 14, 20253.533.683.433.51256.71K
Feb 13, 20253.473.533.293.50205.73K
Feb 12, 20253.143.473.133.46291.88K
Feb 11, 20253.253.283.093.21370.88K
Feb 10, 20253.563.563.233.23441.9K
Feb 07, 20253.713.723.503.50390.8K
Feb 06, 20253.904.093.703.74588.16K
Feb 05, 20253.543.913.503.90701.49K
Feb 04, 20253.513.603.403.50404.62K
Feb 03, 20253.533.693.413.51437.97K
Jan 31, 20253.664.103.553.80687.86K
Jan 30, 20253.703.753.493.54302.07K

Contact Details

Lexington, MA 02421-7305

United States

Website: https://www.agenusbio.comContact: 781 674 4400

About Company

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Company Information

Employees389
Beta1.3
Sales or Revenue$156.31M
5Y Sales Change%0.315%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Frequently Asked Questions

What is the current Agenus Inc. (AGEN) stock price?

Agenus Inc. (NASDAQ: AGEN) stock price is $2.86 in the last trading session. During the trading session, AGEN stock reached the peak price of $3.23 while $2.83 was the lowest point it dropped to. The percentage change in AGEN stock occurred in the recent session was -8.63% while the dollar amount for the price change in AGEN stock was -$0.27.

AGEN's industry and sector of operation?

The NASDAQ listed AGEN is part of Biotechnology industry that operates in the broader Healthcare sector. Agenus Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of AGEN?

Ms. Stephanie Fagan
Chief Communications Officer
Dr. Garo H. Armen Ph.D.
Executive Chairman
Ms. Tracy Mazza Clemente
Chief People Officer
Dr. Jennifer S. Buell Ph.D.
Pres, Chief Executive Officer & Director
Mr. Zack Armen
Head of Investor Relations
Mr. Dhan Chand
Scientific Director & Head of Drug Discovery
Ms. Christine M. Klaskin
Treasurer
Ms. Julie DeSander
Chief Bus. Officer
Craig Winter
Chief Information Officer
Regina Grebla Ph.D.
Vice President of Investor Relations & Communications
Dr. Steven J. O'Day M.D., Ph.D.
Chief Medical Officer
John Castle
Head of Translational Medicine & Bioinformatics
Ms. Robin E. Abrams J.D.
Chief Legal Officer

How AGEN did perform over past 52-week?

AGEN's closing price is 14.4% higher than its 52-week low of $2.50 where as its distance from 52-week high of $19.69 is -85.47%.

How many employees does AGEN have?

Number of AGEN employees currently stands at 389.

Link for AGEN official website?

Official Website of AGEN is: https://www.agenusbio.com

How do I contact AGEN?

AGEN could be contacted at phone 781 674 4400 and can also be accessed through its website. AGEN operates from 3 Forbes Road, Lexington, MA 02421-7305, United States.

How many shares of AGEN are traded daily?

AGEN stock volume for the day was 543.49K shares. The average number of AGEN shares traded daily for last 3 months was 423.15K.

What is the market cap of AGEN currently?

The market value of AGEN currently stands at $67.09M with its latest stock price at $2.86 and 23.46M of its shares outstanding.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph